Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EBIT (2016 - 2025)

Fennec Pharmaceuticals' EBIT history spans 15 years, with the latest figure at $2.2 million for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 336.94% year-over-year to $2.2 million, compared with a TTM value of -$1.5 million through Dec 2025, down 159.03%, and an annual FY2025 reading of -$1.5 million, down 159.0% over the prior year.
  • EBIT for Q4 2025 was $2.2 million at Fennec Pharmaceuticals, up from -$189000.0 in the prior quarter.
  • The five-year high for EBIT was $13.7 million in Q1 2024, with the low at -$7.9 million in Q3 2022.
  • Average EBIT over 5 years is -$2.5 million, with a median of -$3.9 million recorded in 2021.
  • Biggest YoY gain for EBIT was 360.78% in 2024; the steepest drop was 411.5% in 2024.
  • Tracing FENC's EBIT over 5 years: stood at -$4.2 million in 2021, then tumbled by 47.02% to -$6.1 million in 2022, then skyrocketed by 70.37% to -$1.8 million in 2023, then surged by 48.62% to -$934000.0 in 2024, then surged by 336.94% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's EBIT are $2.2 million (Q4 2025), -$189000.0 (Q3 2025), and -$2.7 million (Q2 2025).